Health · Pharma & Biotech · 3 hrs ago
Experimental Cream Shows Early Signs of Reducing Skin Aging
Rubedo Life Sciences, a biotech company based in Mountain View, California, is testing a cream designed to target aging-related cells in the skin.
In a four-week trial involving 11 people with atopic dermatitis, participants’ estimated skin age fell by about two years on average.
The estimate came from an analysis of skin samples using an aging clock, which measures patterns in DNA; it does not prove that skin or the body became functionally younger.
The cream is designed to make senescent cells, which can build up with age and contribute to inflammation, more likely to die.
In a separate trial of 18 people with sun-damage-related actinic keratosis, the cream reduced the total number of lesions by 46 percent after a month.
Rubedo is also studying the drug for psoriasis and sun-damaged skin, and plans to study it for hereditary hair loss.
The results are early, and the company is exploring other uses, including a pill for aging-related metabolic conditions.
Rubedo Life Sciences says its experimental skin cream showed early signs of reducing skin-aging measures in a small clinical trial.
After four weeks, 11 participants with atopic dermatitis had an average estimated reduction of about two years in their skin’s biological age.
The estimate came from an aging clock independently applied to skin samples by Mitra Bio.
Rubedo also reported lower inflammation-related markers and a 10 percent increase in a type of collagen linked to skin structure and elasticity.
The results do not establish that the skin or body became functionally younger.
- Who
- Rubedo Life Sciences tested the cream on 11 people with atopic dermatitis.
- What
- The company reported early signs of reduced skin-aging measures after use of its experimental topical cream.
- When
- The trial lasted four weeks. The company presented data earlier this month at a meeting in Boston.
- Where
- The data were presented at the Aging Research and Drug Discovery meeting in Boston. The trial participants’ location is not stated.
- Why
- The treatment is designed to target cellular senescence, a process in which damaged or stressed cells stop dividing but remain in the body.
This story does not have two clearly opposing sides.
Our idea is to find ways to change the trajectory of how we age
Aging is complex. There are many mechanisms, but cellular senescence is one of them.
It's great to see them doing this work
Rubedo presented data on the cream at the Aging Research and Drug Discovery meeting in Boston.
In a trial of 11 people with atopic dermatitis, participants had an average estimated reduction of about two years in skin biological age.
In a separate trial of 18 people with actinic keratosis, the cream was associated with a 46 percent reduction in total lesions.
- Atopic dermatitis trial
- 11 participants
- Treatment period
- Four weeks
- Average estimated change in skin biological age
- About two years lower
- Individual trial result
- One participant had a reduction of more than 11 years in estimated skin age
- Collagen finding
- 10 percent increase in a type associated with skin elasticity and structure
- Actinic keratosis trial
- 18 people; 46 percent reduction in total lesions after a month
Sources
Related news
Retatrutide led to major weight loss in a trial involving adults with type 2 diabetes
Lenacapavir and cabotegravir controlled HIV in a small patient study
Bristol Myers lung disease drug meets main goal in late-stage trial
FDA approves first new oral antiviral for resistant herpes in nearly 30 years
GLP-1 drugs show potential benefits for heart and metabolic health
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Brazil suspends Peptistrong supplement and orders all batches recalled
Idorsia presents new findings on blood pressure drug aprocitentan
Personalized cancer vaccine succeeds in phase 3 melanoma trial
Study links GLP-1 drug use with more reported nail problems
